A new tirzepatide safety meta-analysis, focused on higher-risk patients

A systematic review and meta-analysis of 21 placebo-controlled trials in patients at increased cardiovascular risk found no clear difference in serious adverse events with tirzepatide, while gastrointestinal side effects remained more common. Mortality evidence was sparse.